Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
dc.contributor.author | Ahmed, A | |
dc.contributor.author | Felmlee, Daniel | |
dc.date.accessioned | 2018-07-30T12:56:15Z | |
dc.date.available | 2018-07-30T12:56:15Z | |
dc.date.issued | 2015-12-18 | |
dc.identifier.issn | 1999-4915 | |
dc.identifier.issn | 1999-4915 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/11963 | |
dc.description.abstract |
There has been a remarkable transformation in the treatment of chronic hepatitis C in recent years with the development of direct acting antiviral agents targeting virus encoded proteins important for viral replication including NS3/4A, NS5A and NS5B. These agents have shown high sustained viral response (SVR) rates of more than 90% in phase 2 and phase 3 clinical trials; however, this is slightly lower in real-life cohorts. Hepatitis C virus resistant variants are seen in most patients who do not achieve SVR due to selection and outgrowth of resistant hepatitis C virus variants within a given host. These resistance associated mutations depend on the class of direct-acting antiviral drugs used and also vary between hepatitis C virus genotypes and subtypes. The understanding of these mutations has a clear clinical implication in terms of choice and combination of drugs used. In this review, we describe mechanism of action of currently available drugs and summarize clinically relevant resistance data. | |
dc.format.extent | 6716-6729 | |
dc.format.medium | Electronic | |
dc.language | en | |
dc.language.iso | en | |
dc.publisher | MDPI | |
dc.subject | resistance | |
dc.subject | hepatitis C | |
dc.subject | direct acting antivirals | |
dc.subject | breakthrough variants | |
dc.title | Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals | |
dc.type | journal-article | |
dc.type | Journal Article | |
dc.type | Review | |
plymouth.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000367536700042&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008 | |
plymouth.issue | 12 | |
plymouth.volume | 7 | |
plymouth.publication-status | Published online | |
plymouth.journal | Viruses | |
dc.identifier.doi | 10.3390/v7122968 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/Peninsula Medical School | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
dc.publisher.place | Switzerland | |
dcterms.dateAccepted | 2015-12-08 | |
dc.identifier.eissn | 1999-4915 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.3390/v7122968 | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2015-12-18 | |
rioxxterms.type | Journal Article/Review |